Media professionals

  • Email
  • Help

Working with the media

Welcome to the European Medicines Agency’s online media centre. This page highlights information which is of specific interest to media professionals. 

The page is kept updated with news, events and information for journalists with a professional interest in the development and availability of medicines in the European Union.

For more information, please contact the EMA press office

Featured information

News for media professionals

Events of interest

  • 08/12/2015


    European network of paediatric research-European Medicines Agency meeting on rare gastrointestinal and liver diseases

    The European network of paediatric research (Enpr-EMA) is organising a one-day meeting. The morning session is dedicated to the Paediatric European Digestive Diseases Clinical Research Network (PEDDCReN) to present to industry representatives their planned initiative to prospectively identify the incidence and prevalence of rare and very rare diseases in the field of paediatric gastroenterology and hepatology by establishing a European registry for these rare diseases and to discuss with industry how best to use this to work for developing research in these unique groups of patients. The afternoon session is organised together with the European Cystic Fibrosis Society and will focus on gastrointestinal outcome measures for clinical trials with new medicines targeting the basic defect in cystic fibrosis, so-called CFTR modulators. ... Read more

  • 09/11/2015


    Second industry stakeholder platform on the operation of the centralised procedure for human medicinal products

    The objective of this series of semi-annual meetings between regulators and representatives of industry stakeholder organisations is to provide an opportunity for both general updates and more focused discussions on specific processes or issues to support continuous improvement, and generally to foster a constructive dialogue with industry stakeholders. At the second meeting, the detailed report on the survey on post-authorisation procedures is discussed. Furthermore, specific aspects of variation management for risk management plan updates, experience with the review of mock-ups and specimens as well as a progress report on the revision of guidelines on early access tools is addressed. Registration by invitation only. ... Read more

  • 19/11/2015 - 20/11/2015

    The annual European Medicines Agency review of the year and outlook for 2016

    This key end of year conference will provide an annual review of the activities of the European Medicines Agency (EMA) and the national agencies within the European regulatory system, providing European regulatory professionals a chance to reflect and plan for the challenges ahead. The conference will discuss major areas of medicines legislation coordinated by the EMA and provide practical advice on the work of EMA within the European regulatory network and on how national agencies contribute. It will feature a wide range of speakers and panellists from senior agency personnel to senior leadership, patient organisation representatives, industry leaders, pan-European policymakers and consultants. ... Read more

  • 09/10/2015


    Stakeholder meeting on product shortages due to manufacturing and quality problems: developing a proactive approach to prevention

    In October 2013, a workshop held at the European Medicines Agency (EMA) led to the formation of an inter-industry association taskforce to propose possible solutions to the root causes of shortages due to manufacturing and quality problems. EMA is hosting a follow-up workshop on 9 October 2015 to discuss the solutions proposed by industry associations. Registration by invitation only. A live broadcast of the workshop will be available. ... Read more

  • 07/12/2015


    Demonstrating significant benefit of orphan medicines concepts, methodology, and impact on access

    This workshop aims to help clarify the concept and demonstration of significant benefit of new orphan medicines over existing treatments; discuss existing methodologies for comparative efficacy and effectiveness and for major contribution to patient care, including patient preferences, and how these could be applied in demonstrating significant benefit at marketing authorisation; and discuss the impact of significant benefit on health-technology-assessment (HTA) evaluation, pricing decisions and patient access. The workshop is targeted at medicine developers, regulators, healthcare professionals, academia, patients, HTA bodies and healthcare payers. Registration has been closed early due to high demand, but it will be possible to follow the live broadcast. ... Read more

  • See all Events of interest

Information for:

Find information for...